ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly effient (prasugrel) — U.S. revenue ($M) [legacy] ($M)
Quarterly figures from Eli Lilly's filings and investor materials
Latest, Q4 2018
8.70
Period ended Dec 31, 2018
Change on a year earlier
-82.4%
49.3 in Q4 2017
History
8 quarters
Since Q1 2017
Sources
4
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Effient (prasugrel) — U.S. revenue ($M) [legacy] ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2018 | Dec 31, 2018 | 8.70 | -82.4% | Form 10-K (filed 2019-02-19) ↗ |
| Q3 2018 | Sep 30, 2018 | 30.2 | -29.3% | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2018 | Jun 30, 2018 | 13.3 | -89.8% | Form 10-Q (filed 2018-07-25) ↗ |
| Q1 2018 | Mar 31, 2018 | 15.9 | -86.4% | Form 10-Q (filed 2018-04-27) ↗ |
| Q4 2017 | Dec 31, 2017 | 49.3 | – | Form 10-K (filed 2019-02-19) ↗ |
| Q3 2017 | Sep 30, 2017 | 42.7 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 131 | – | Form 10-Q (filed 2018-07-25) ↗ |
| Q1 2017 | Mar 31, 2017 | 117 | – | Form 10-Q (filed 2018-04-27) ↗ |
Cite this data
StockData. (2026). Eli Lilly Effient (prasugrel) — U.S. revenue ($M) [legacy] ($M), quarterly Q1 2017–Q4 2018 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_effient_us
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.